New mRNA vaccines aim to outsmart evolving COVID variants

NCT ID NCT06585241

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study tests several updated mRNA COVID-19 vaccines designed to target new variants of the virus. About 1,144 adults and children with certain risk factors will receive a vaccine dose. Researchers will measure how well the vaccines boost immunity and check for any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CenExel
RECRUITING

Atlanta, Georgia, 30331, United States
CenExel
RECRUITING

Decatur, Georgia, 30030, United States
Richard Bennett - Clinical Research Partners
RECRUITING

Richmond, Virginia, 23226, United States
Velocity Clinical Research
RECRUITING

Baton Rouge, Louisiana, 70809, United States
Velocity Clinical Research
RECRUITING

Gulfport, Mississippi, 39503, United States
Velocity Clinical Research
RECRUITING

Omaha, Nebraska, 68134, United States

Conditions

Explore the condition pages connected to this study.

SARS-COV-2